1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > United Biomedical, Inc. - Product Pipeline Review - 2015

United Biomedical, Inc. - Product Pipeline Review - 2015

  • October 2015
  • -
  • Global Markets Direct
  • -
  • 28 pages

United Biomedical, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘United Biomedical, Inc. - Product Pipeline Review - 2015’, provides an overview of the United Biomedical, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of United Biomedical, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of United Biomedical, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of United Biomedical, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the United Biomedical, Inc.’s pipeline products

Reasons to buy

- Evaluate United Biomedical, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of United Biomedical, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the United Biomedical, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of United Biomedical, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of United Biomedical, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of United Biomedical, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

United Biomedical, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
United Biomedical, Inc. Snapshot 5
United Biomedical, Inc. Overview 5
Key Information 5
Key Facts 5
United Biomedical, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
United Biomedical, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
United Biomedical, Inc. - Pipeline Products Glance 12
United Biomedical, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
United Biomedical, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
United Biomedical, Inc. - Drug Profiles 14
UB-421 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
HIV vaccine 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
HIV vaccine 1 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Synthetic Peptide for Undisclosed Indication 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
TW-01003 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Vaccine for Allergy 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
United Biomedical, Inc. - Pipeline Analysis 20
United Biomedical, Inc. - Pipeline Products by Target 20
United Biomedical, Inc. - Pipeline Products by Route of Administration 21
United Biomedical, Inc. - Pipeline Products by Molecule Type 22
United Biomedical, Inc. - Pipeline Products by Mechanism of Action 23
United Biomedical, Inc. - Recent Pipeline Updates 24
United Biomedical, Inc. - Dormant Projects 25
United Biomedical, Inc. - Locations And Subsidiaries 26
Head Office 26
Other Locations and Subsidiaries 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 27
Disclaimer 28

List of Tables
United Biomedical, Inc., Key Information 5
United Biomedical, Inc., Key Facts 5
United Biomedical, Inc. - Pipeline by Indication, 2015 7
United Biomedical, Inc. - Pipeline by Stage of Development, 2015 8
United Biomedical, Inc. - Monotherapy Products in Pipeline, 2015 9
United Biomedical, Inc. - Partnered Products in Pipeline, 2015 10
United Biomedical, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11
United Biomedical, Inc. - Phase II, 2015 12
United Biomedical, Inc. - Preclinical, 2015 13
United Biomedical, Inc. - Pipeline by Target, 2015 20
United Biomedical, Inc. - Pipeline by Route of Administration, 2015 21
United Biomedical, Inc. - Pipeline by Molecule Type, 2015 22
United Biomedical, Inc. - Pipeline Products by Mechanism of Action, 2015 23
United Biomedical, Inc. - Recent Pipeline Updates, 2015 24
United Biomedical, Inc. - Dormant Developmental Projects,2015 25
United Biomedical, Inc., Subsidiaries 26

List of Figures
United Biomedical, Inc. - Pipeline by Top 10 Indication, 2015 7
United Biomedical, Inc. - Pipeline by Stage of Development, 2015 8
United Biomedical, Inc. - Monotherapy Products in Pipeline, 2015 9
United Biomedical, Inc. - Pipeline by Top 10 Target, 2015 20
United Biomedical, Inc. - Pipeline by Top 10 Molecule Type, 2015 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Macular Edema - Pipeline Review, H2 2016

Macular Edema - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Macular Edema - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema – Pipeline Review, H2 2016, provides an overview of ...

Alliqua BioMedical, Inc. (ALQA) - Financial and Strategic SWOT Analysis Review

Alliqua BioMedical, Inc. (ALQA) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Alliqua BioMedical, Inc. (Alliqua BioMedical) formerly HepaLife Technologies Inc. is a medical device company that offers wound care solutions. The company offers wound care, transdermal drug delivery, ...

Entest BioMedical Inc. (ENTB) - Financial and Strategic SWOT Analysis Review

Entest BioMedical Inc. (ENTB) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Entest BioMedical Inc. (Entest BioMedical) is a biomedical research company that develops immuno-therapeutic treatments that address illnesses and maladies in both veterinary and human medicine. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.